Wave Life Sciences Ltd. (WVE) Earnings
Wave Life Sciences Ltd. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $-0.31. WVE has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise +61.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 28, 2026 | $-0.34 | $-0.13 | +61.8% | $38M | +352.6% |
| Jul 30, 2025 | $-0.29 | $-0.31 | -6.9% | $9M | -11.7% |
| May 8, 2025 | $-0.27 | $-0.29 | -7.4% | $9M | -36.4% |
| Mar 4, 2025 | $-0.17 | $0.17 | +200.0% | $84M | +588.3% |
| May 9, 2024 | $-0.18 | $-0.24 | -33.3% | $13M | -45.4% |
| Mar 6, 2024 | $-0.19 | $-0.15 | +21.1% | $29M | +46.3% |
| Nov 9, 2023 | $-0.18 | $0.07 | +138.9% | $49M | +147.8% |
| Aug 3, 2023 | $-0.32 | $-0.20 | +37.5% | $22M | +178.4% |
| May 3, 2023 | $0.06 | $-0.27 | -550.0% | $13M | -60.0% |
| Mar 22, 2023 | $-0.42 | $-0.47 | -11.9% | $1M | -82.5% |
| Nov 10, 2022 | $-0.48 | $-0.42 | +12.5% | $285000 | -96.5% |
| Aug 11, 2022 | $-0.56 | $-0.62 | -10.7% | $375000 | -90.2% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 28, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Accelerating development of WVE007 for obesity, with Phase 2A trial preparation. - RNA editing program WVE006 showing potential in AATD with Restoration 2 trial data. - Advancing WVE008 for PNPLA3 liver disease. - Proprietary chemistry translating in the clinic. - Pipeline of next generation candidates.
Guidance
- Cash to cash equivalents will be sufficient to fund operations into the third quarter of 2028. - Rapidly advancing multiple studies of WVE007. - Delivering new WVE006 data in May. - Progressing WVE008 towards the clinic.
Segment performance
Revenue for the first quarter of 2026 was $38.2 million. Research and development expenses were $47.4 million. G&A expenses were $22.1 million. Net loss was $26.1 million. Ended the first quarter with $544.6 million in cash to cash equivalents. WVE007 is rapidly advancing with Phase 2A trial preparation. WVE006's Restoration 2 trial shows potential for AATD. WVE008 is progressing towards the clinic.